Analyst firms · BofA Securities · REGN

BofA Securities REGN price target and rating history

Regeneron Pharmaceuticals Inc. (REGN) · Health Care

BofA Securities rates Regeneron Pharmaceuticals Inc. (REGN) Buy with a $860 price target, as of its latest action on Jan 7, 2026. It has published 3 rating actions on REGN since January 2022, including 1 upgrade and 1 downgrade. Across 9 firms with a REGN price target in the last 12 months, the median target is $798. BofA Securities's $860 is 8% above that.

Current rating
Buy
Price target
$860
Median target, all firms
$798
Actions on REGN
3

BofA Securities price target on REGN

$860$713$5652023202420252026
BofA Securities price target on REGN, each point a stated target, January 2022 to January 2026.

Every BofA Securities rating on REGN

How other firms rate REGN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$850Oct 1, 2026
CitigroupNeutral$700May 18, 2026
Leerink PartnersMarket Perform$641May 18, 2026
Piper SandlerOverweight$875Mar 31, 2026
BarclaysOverweight$923Mar 6, 2026
BofA SecuritiesBuy$860Jan 7, 2026
Morgan StanleyEqual-Weight$767Dec 3, 2025
Truist SecuritiesBuy$798Nov 24, 2025
HSBCBuy$255Nov 24, 2025

Questions about BofA Securities and REGN

What is BofA Securities's price target for REGN?
BofA Securities's latest stated price target for Regeneron Pharmaceuticals Inc. (REGN) is $860, from its action on Jan 7, 2026.
What is BofA Securities's rating on REGN?
BofA Securities rates REGN Buy, a bullish rating, as of Jan 7, 2026.
When did BofA Securities last change its view on REGN?
On Jan 7, 2026, BofA Securities upgrades to Buy from Underperform, price target $860.
How does BofA Securities's REGN target compare with other analysts?
Across 9 firms with a REGN price target in the last 12 months, the median target is $798. BofA Securities's $860 is 8% above that.

More REGN rating histories

All BofA Securities ratingsREGN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.